Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial. Clinical utility of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback